Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y, Broeks A, Giardiello D, Hauptmann M, Jóźwiak K, Koop EA, Opdam M, Siesling S, Sonke GS, Stathonikos N, Ter Hoeve ND, van der Wall E, van Deurzen CHM, van Diest PJ, Voogd AC, Vreuls W, Linn SC, Dackus GMHE, Schmidt MK. Wang Y, et al. Among authors: dackus gmhe. Eur J Cancer. 2023 Dec;195:113401. doi: 10.1016/j.ejca.2023.113401. Epub 2023 Oct 30. Eur J Cancer. 2023. PMID: 37925965 Free article.
Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Jóźwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC. de Jong VMT, et al. Among authors: dackus gmhe. J Clin Oncol. 2022 Jul 20;40(21):2361-2374. doi: 10.1200/JCO.21.01536. Epub 2022 Mar 30. J Clin Oncol. 2022. PMID: 35353548 Free PMC article.
Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.
Dackus GM, Ter Hoeve ND, Opdam M, Vreuls W, Varga Z, Koop E, Willems SM, Van Deurzen CH, Groen EJ, Cordoba A, Bart J, Mooyaart AL, van den Tweel JG, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Amant F, Broeks A, Kerkhoven R, Stathonikos N, Veta M, Voogd A, Jozwiak K, Hauptmann M, Hoogstraat M, Schmidt MK, Sonke G, van der Wall E, Siesling S, van Diest PJ, Linn SC. Dackus GM, et al. BMJ Open. 2017 Nov 14;7(11):e017842. doi: 10.1136/bmjopen-2017-017842. BMJ Open. 2017. PMID: 29138205 Free PMC article.
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Geenen JJJ, Dackus GMHE, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema ADR, Beijnen JH, Schellens JHM, Linn SC. Geenen JJJ, et al. Among authors: dackus gmhe. Int J Cancer. 2021 Jun 15;148(12):3041-3050. doi: 10.1002/ijc.33498. Epub 2021 Feb 27. Int J Cancer. 2021. PMID: 33539540 Free PMC article. Clinical Trial.
Response to Klar and Adams.
Dackus GMHE, Jóźwiak K, Hauptmann M, Linn SC. Dackus GMHE, et al. J Natl Cancer Inst. 2022 Jan 11;114(1):167-168. doi: 10.1093/jnci/djab153. J Natl Cancer Inst. 2022. PMID: 34396390 Free PMC article. No abstract available.
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC. Schouten PC, et al. Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0. Trials. 2016. PMID: 27323902 Free PMC article. Clinical Trial.
17 results